Not received any observation from USFDA audit: Claris
Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation.
NEW DELHI: Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation.“Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s),” the company said in a BSE filing today.
The company shares were trading up by 4.34 per cent at Rs. 341.25 on the BSE.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions